BRPI0411808A - formulações farmacêuticas de compostos para inibição de amilóide - Google Patents

formulações farmacêuticas de compostos para inibição de amilóide

Info

Publication number
BRPI0411808A
BRPI0411808A BRPI0411808-1A BRPI0411808A BRPI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
inhibiting compounds
amyloid
amyloid inhibiting
methods
Prior art date
Application number
BRPI0411808-1A
Other languages
English (en)
Inventor
Audley Legore
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of BRPI0411808A publication Critical patent/BRPI0411808A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS DE COMPOSTOS PARA INIBIçãO DE AMILóIDE". São descritos formulações terapêuticas e métodos para inibir a deposição de amilóide em um indivíduo, qualquer que seja sua avaliação clínica. As formulações terapêuticas e métodos para prevenir ou tratar amiloidose e/ou doença relacionada ao amilóide são também descritos.
BRPI0411808-1A 2003-06-23 2004-06-21 formulações farmacêuticas de compostos para inibição de amilóide BRPI0411808A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48098403P 2003-06-23 2003-06-23
US51211603P 2003-10-17 2003-10-17
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
PCT/IB2004/002381 WO2004112762A2 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (1)

Publication Number Publication Date
BRPI0411808A true BRPI0411808A (pt) 2006-08-08

Family

ID=33545348

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411808-1A BRPI0411808A (pt) 2003-06-23 2004-06-21 formulações farmacêuticas de compostos para inibição de amilóide

Country Status (18)

Country Link
US (2) US20050142191A1 (pt)
EP (2) EP1635799B1 (pt)
JP (1) JP4903561B2 (pt)
CN (1) CN103550196A (pt)
AT (1) ATE438391T1 (pt)
AU (2) AU2004248995B2 (pt)
BR (1) BRPI0411808A (pt)
CA (1) CA2529268C (pt)
DE (1) DE602004022408D1 (pt)
DK (1) DK1635799T3 (pt)
ES (1) ES2328818T3 (pt)
IL (1) IL172193A0 (pt)
MX (1) MXPA05013974A (pt)
NZ (1) NZ544685A (pt)
PL (1) PL1635799T3 (pt)
PT (1) PT1635799E (pt)
SI (1) SI1635799T1 (pt)
WO (1) WO2004112762A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543319A (en) * 1999-04-28 2007-06-29 Neurochem Int Ltd Compositions and methods for treating amyloidosis using sulphonate derivatives
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
KR101608445B1 (ko) * 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
JP2012505162A (ja) * 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用
EP2944022B1 (en) 2013-01-08 2019-12-25 Rambus Inc. Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
PT3347002T (pt) 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
WO2018213589A1 (en) 2017-05-17 2018-11-22 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
EP4514335A1 (en) 2022-04-28 2025-03-05 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
EP4626416A1 (en) 2022-12-02 2025-10-08 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3390188C2 (de) 1982-09-08 1987-07-23 Mitsui Toatsu Chemicals Verfahren zur herstellung einer Aminoalkylsulfonsäure
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
JPH06510760A (ja) 1991-08-27 1994-12-01 ジ・アップジョン・カンパニー 代謝障害および代謝の治療法
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
KR100388569B1 (ko) * 1994-04-22 2003-10-11 야마노우치세이야쿠 가부시키가이샤 결장특이적약물방출용경구약제학적제제
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
WO1997009925A2 (en) * 1995-09-12 1997-03-20 The General Hospital Corporation Method for early detection of ovarian cancer
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
MXPA00007815A (es) * 1998-02-11 2002-04-24 Neurochem Inc Metodo para modular la activacion de macrofagos.
WO1999059571A1 (en) * 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
NZ543319A (en) * 1999-04-28 2007-06-29 Neurochem Int Ltd Compositions and methods for treating amyloidosis using sulphonate derivatives
AU5994900A (en) 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
FR2832928B1 (fr) * 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
JP4354180B2 (ja) * 2001-12-26 2009-10-28 武田薬品工業株式会社 軽度認知障害治療剤
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클

Also Published As

Publication number Publication date
AU2010201299A1 (en) 2010-04-22
AU2004248995A1 (en) 2004-12-29
AU2004248995B2 (en) 2010-01-07
ATE438391T1 (de) 2009-08-15
EP2127648A1 (en) 2009-12-02
CN103550196A (zh) 2014-02-05
CA2529268C (en) 2013-10-29
ES2328818T3 (es) 2009-11-18
WO2004112762A3 (en) 2005-06-02
CA2529268A1 (en) 2004-12-29
US8835500B2 (en) 2014-09-16
EP1635799A2 (en) 2006-03-22
SI1635799T1 (sl) 2009-12-31
IL172193A0 (en) 2009-02-11
DE602004022408D1 (de) 2009-09-17
PT1635799E (pt) 2009-09-23
US20090182056A1 (en) 2009-07-16
DK1635799T3 (da) 2009-11-23
MXPA05013974A (es) 2006-03-09
EP1635799B1 (en) 2009-08-05
JP2007518672A (ja) 2007-07-12
US20050142191A1 (en) 2005-06-30
JP4903561B2 (ja) 2012-03-28
NZ544685A (en) 2009-05-31
WO2004112762A2 (en) 2004-12-29
PL1635799T3 (pl) 2010-01-29

Similar Documents

Publication Publication Date Title
DK1635799T3 (da) Farmaceutiske formuleringer af amyloidinhiberende forbindelser
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
IS7670A (is) Samsett meðferð fyrir offjölgunar sjúkdóma
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
PT1781298E (pt) Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
ATE369136T1 (de) Therapeutische behandlung
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
DE50313329D1 (de) 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
IS8477A (is) Beta-laktöm til að meðhöndla MTK sjúkdóma
EP1582216A4 (en) CURE FOR PEMPHIGOID
HK1091715A (en) Therapeutic agents useful for treating pain

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BELLUS HEALTH (INTERNATIONAL) LIMITED (CH)

Free format text: NOME ALTERADO DE: NEUROCHEM (INTERNATIONAL) LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]